Ukraine's Intelligence Service reported the information.According to the report, after the start of the full-scale war against Ukraine, international pharmaceutical companies massively halted multicenter clinical trials in Russia.The number of such studies dropped nearly 20-fold — from 376 in 2021 to just 18 in 2024. This primarily concerns drugs for treating cancer, HIV, hepatitis, and other serious illnesses, as well as alternatives to existing medications.Intelligence noted that, although these drugs are not formally subject to international sanctions, importing new medications into Russia has become virtually impossible: Moscow does not recognize the results of foreign clinical trials without the participation of Russian patients and doctors.Before the invasion, this allowed patients in Russia to access new drugs 3–4 years earlier.Due to isolation, such delays have already had consequences — for example, the antiviral hepatitis C drug sofosbuvir, approved in the U.S. in 2013, only became available in Russia four years later, despite its nearly 100% effectiveness.In September, the Yellow Ribbon partisan movement reported that Russia was bringing expired or nearly expired medicines into the temporarily occupied territories of Kherson region.